These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Development and clinical consequences of white matter lesions in Fabry disease: a systematic review. Körver S; Vergouwe M; Hollak CEM; van Schaik IN; Langeveld M Mol Genet Metab; 2018 Nov; 125(3):205-216. PubMed ID: 30213639 [TBL] [Abstract][Full Text] [Related]
8. Enzyme replacement therapy stabilized white matter lesion progression in Fabry disease. Fellgiebel A; Gartenschläger M; Wildberger K; Scheurich A; Desnick RJ; Sims K Cerebrovasc Dis; 2014; 38(6):448-56. PubMed ID: 25502511 [TBL] [Abstract][Full Text] [Related]
9. Fabry Disease: prevalence of affected males and heterozygotes with pathogenic Doheny D; Srinivasan R; Pagant S; Chen B; Yasuda M; Desnick RJ J Med Genet; 2018 Apr; 55(4):261-268. PubMed ID: 29330335 [TBL] [Abstract][Full Text] [Related]
10. The Frequency of Fabry Disease among Young Cryptogenic Stroke Patients in the City of Sakarya. Gündoğdu AA; Kotan D; Alemdar M J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):1334-1340. PubMed ID: 28283366 [TBL] [Abstract][Full Text] [Related]
11. Fabry Disease in Young Ischemic Stroke Patients in Northern Israel. Afanasiev S; Telman G; Hadad R; Altarescu G J Stroke Cerebrovasc Dis; 2020 Dec; 29(12):105398. PubMed ID: 33096490 [TBL] [Abstract][Full Text] [Related]